11,311 Results

Phase III study of Nucala meets primary endpoint in Hypereosinophilic Syndrome.- GSK

 Added 22 hours ago

GlaxoSmithKline announced positive results from the pivotal study of Nucala (mepolizumab) in the treatment of patients living with Hypereosinophilic Syndrome...

Phase III CLEAR Wisdom trial of EYC 1002(bempedoic acid 180 mg) in atherosclerotic CV disease + HFH published in JAMA.- Daiichi Sankyo

 Added 22 hours ago

Daiichi Sankyo Europe has announced the publication of results from the Phase III CLEAR Wisdom trial of EYC 1002 (bempedoic...

Study 017 trial of safety and efficacy of YKP 3089 in focal seizures published in The Lancet Neurology.- SK Life Science

 Added 22 hours ago

SK Life Science announced The Lancet Neurology has published results from Study 017, a multicenter, double-blind, randomized, placebo-controlled, dose-response study...

AZD 6244 filed with FDA for NF1 and plexiform neurofibromas and given priority review.- AstraZeneca and Merck Inc

 Added 22 hours ago

AstraZeneca and Merck Inc announced that the FDA has accepted a New Drug Application (NDA) and granted Priority Review for...

Boehringer and Eli Lilly announce outcome of FDA advisory committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes.

 Added 1 day ago

The FDA Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14 to 2 that the benefits of empagliflozin 2.5 mg...

COAST-X phase III trial of Taltz meets primary and secondary endpoints in axial spondyloarthritis.- Eli Lilly

 Added 2 days ago

Eli Lilly presented detailed results demonstrating Taltz (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a 52-week...

Actelion Pharma withdraws filing of Opsumit for CTEPH

 Added 2 days ago

Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has announced its decision to voluntarily withdraw...

GW Pharmaceuticals receives positive NICE recommendation for Epidyolex for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

 Added 2 days ago

GW Pharmaceuticals plc announces that two of its medicines, Epidyolex (cannabidiol) oral solution and Sativex (nabiximols), have been recommended by...

Phase III CONFIRM study of Variquel meets primary endpoint in hepatorenal syndrome type 1.- Mallinckrodt

 Added 2 days ago

Mallinckrodt announced results from its pivotal Phase III CONFIRM study to assess the efficacy and safety of its investigational agent...

Lilly presents 52-week head-to-head (SPIRIT-H2H) data from Taltz v. Humira trial in psoriatic arthritis.

 Added 2 days ago

Eli Lilly and Company announced the 52-week results from the Phase IIIb/IV SPIRIT-Head-to-Head (H2H) study of Taltz (ixekizumab) versus Humira...

Load more